Johnson Financial Group Inc. Grows Stake in IDEXX Laboratories, Inc. $IDXX

Johnson Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2,994.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,671 shares of the company’s stock after acquiring an additional 1,617 shares during the period. Johnson Financial Group Inc.’s holdings in IDEXX Laboratories were worth $939,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. State Street Corp raised its holdings in IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after purchasing an additional 138,956 shares in the last quarter. J. Stern & Co. LLP raised its holdings in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after buying an additional 181,955 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $552.46 on Wednesday. The firm’s fifty day simple moving average is $555.50 and its 200-day simple moving average is $597.62. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The stock has a market capitalization of $43.58 billion, a price-to-earnings ratio of 40.68, a PEG ratio of 3.08 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.